Dawnrays Pharmaceutical (Holdings) Ltd is an investment holding company mainly engaged in the development, manufacture and sale of non-patented drugs. The Company operates its business through two segments. The finished drugs segment is engaged in the manufacture and sale of finished drugs. The intermediates and bulk medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines.

Employees

1,074

Sector

Pharmaceuticals

Calendar

09-22 Ex-dividend date - 0.015 HKD

More about the company

Quotes

Date	Price	Change	Volume
17/09/26	HK$0.9800	-0.51%	92,000
16/09/26	HK$0.9850	+0.51%	44,000
15/09/26	HK$0.9800	-0.51%	176,000
14/09/26	HK$0.9850	-1.01%	244,000
11/09/26	HK$0.9950	0.00%	76,000

Delayed Quote Hong Kong S.E.

More quotes

Market Closed - Hong Kong S.E. 11:08:09 17/09/2026 +03			5-day change	1st Jan Change
0.9800 ^HKD	-0.51%		-1.51%	-19.67%

08-28	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-28	Dawnrays Pharmaceutical Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2026, Payable on 09 October 2026	CI

Market Cap	1.27B 1.48B 189M 164M 155M 141M 263M 18.14B 265M 1.85B 714M 9.2B 710M 694M 29.32B	P/E 2024	3.06x	P/E 2025	7.83x
Enterprise Value	-459M -537M -68.47M -59.34M -56.08M -50.92M -95.43M -6.57B -96M -670M -259M -3.33B -257M -252M -10.62B	EV / Sales 2024	0.14x	EV / Sales 2025	-0.06x
Free-Float	32.6%	Yield 2024	5.16%	Yield 2025	5.16%

08-28	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-28	Dawnrays Pharmaceutical Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2026, Payable on 09 October 2026	CI
05-29	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg	CI
05-22	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025	CI
03-27	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-27	Dawnrays Pharmaceutical (Holdings) final dividend of HK$0.048 per share	RE
03-27	Dawnrays Pharmaceutical Limited Proposes Final Cash Dividend for the Year Ended December 31, 2025, Payable on June 12, 2026	CI
22/08/25	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
22/08/25	Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2025, Payable on 03 October 2025	CI
22/08/25	Dawnrays pharmaceutical reports HY net income attributable of RMB104.6 mln	RE
31/07/25	Dawnrays Pharmaceutical Limited Announces Appointment of Hu Shuo as Non-Executive Director with Effect from 1 August 2025	CI
23/05/25	Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended 31 December 2024	CI
23/05/25	Dawnrays Pharmaceutical Limited Declares Special Dividend for the Year Ended 31 December 2024	CI

20/04/21	Dawnrays Pharmaceutical : Form of proxy for use at the Annual General Meeting of the Company to be held on Friday, 28 May 2021 (or at any adjournment thereof)	PU
20/04/21	Dawnrays Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	PU
23/09/20	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
22/09/20	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
21/09/20	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU

Dawnrays Pharmaceutical (Holdings) Limited Stock

Stocks

2348

KYG2687M1006

Pharmaceuticals

Valuation: Dawnrays Pharmaceutical (Holdings) Limited

Chart: Dawnrays Pharmaceutical (Holdings) Limited

Latest news: Dawnrays Pharmaceutical (Holdings) Limited

Press Releases: Dawnrays Pharmaceutical (Holdings) Limited

Quotes and Performance

Price Extremes

Managers and Directors: Dawnrays Pharmaceutical (Holdings) Limited

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-0.51%
1 week	-1.51%
Current month	-3.92%
1 month	-2.00%
3 months	-5.77%
6 months	-13.27%
Current year	-19.67%

1 week	0.98	1
1 month	0.98	1.05
Current year	0.98	1.22
1 year	0.98	1.26
3 years	0.98	1.47
5 years	0.98	1.76
10 years	0.84	2.75

Manager	Title	Age	Since
Li Wei Yu CEO	Chief Executive Officer	56	13/09/2024
Yi jun Wu DFI	Director of Finance/CFO	61	-
Michelle Li IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Kei Ling Li CHM	Chairman	77	01/10/2002
Yung Lai Hung BRD	Director/Board Member	81	01/10/2002
Hong Man Leung BRD	Director/Board Member	51	01/11/2005

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/4/26 A	Kei Ling Li	Other	Chairman	60,000	0.0040%
9/4/26 A	Fortune United Group Ltd	Other	Company	60,000	0.0040%
9/3/26 A	Fortune United Group Ltd	Other	Company	104,000	0.0069%

	2024	2025
Net sales	1.06B 1.24B 158M 137M 129M 118M 220M 15.16B 222M 1.55B 597M 7.69B 594M 581M 24.52B	1.23B 1.44B 184M 159M 150M 136M 256M 17.6B 257M 1.79B 693M 8.93B 689M 674M 28.46B
Net income	565M 661M 84.23M 72.99M 68.99M 62.63M 117M 8.08B 118M 824M 318M 4.1B 316M 309M 13.06B	214M 250M 31.9M 27.64M 26.13M 23.72M 44.46M 3.06B 44.72M 312M 121M 1.55B 120M 117M 4.95B
Net Debt	-1.57B -1.84B -235M -203M -192M -174M -327M -22.5B -329M -2.29B -886M -11.41B -881M -861M -36.37B	-1.73B -2.02B -258M -223M -211M -191M -359M -24.7B -361M -2.52B -973M -12.53B -967M -946M -39.94B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED	-0.51%	-1.51%	-19.67%	-13.27%	189M
ELI LILLY AND COMPANY	+0.15%	+1.21%	+48.79%	+97.65%	1,014B
JOHNSON & JOHNSON	+0.03%	+0.07%	+51.47%	+65.55%	644B
ABBVIE INC.	-0.20%	+4.62%	+21.39%	+72.57%	464B
ROCHE HOLDING AG	-0.77%	+4.28%	+38.36%	+39.68%	354B
NOVARTIS AG	+0.74%	+2.66%	+19.20%	+25.10%	265B
ASTRAZENECA PLC	+0.98%	+4.34%	+7.65%	+14.35%	253B
AMGEN INC.	+0.19%	-3.81%	+37.81%	+44.35%	203B
NOVO NORDISK A/S	+0.74%	-3.89%	-25.53%	-57.70%	186B
GILEAD SCIENCES, INC.	+0.94%	+1.39%	+33.21%	+95.16%	183B
Average	+0.23%	+0.86%	+21.27%	+38.35%	356.7B
Weighted average by Cap.	+0.16%	+1.41%	+34.25%	+60.26%